686271-02-3Relevant articles and documents
Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives
Hutchinson, Douglas K.,Rosenberg, Teresa,Klein, Larry L.,Bosse, Todd D.,Larson, Daniel P.,He, Wenping,Jiang, Wen W.,Kati, Warren M.,Kohlbrenner, William E.,Liu, Yaya,Masse, Sherie V.,Middleton, Tim,Molla, Akhteruzzaman,Montgomery, Debra A.,Beno, David W.A.,Stewart, Kent D.,Stoll, Vincent S.,Kempf, Dale J.
scheme or table, p. 3887 - 3890 (2009/04/07)
4,4-Dialkyl-1-hydroxy-3-oxo-3.4-dihydronaphthalene-3-yl benzothiadiazine derivatives were synthesized and evaluated as inhibitors of genotypes 1a and 1b HCV NS5B polymerase. A number of these compounds exhibited potent activity against genotypes 1a and 1b HCV polymerase in both enzymatic and cell culture activities. A representative compound also showed favorable pharmacokinetics in the rat.
ANTI-INFECTIVE AGENTS
-
Page/Page column 131, (2010/02/11)
Compounds having the formula (I) are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
Anti-infective agents
-
Page 118, (2010/02/06)
Compounds having the formula are hepatitis C (HCV) polymerase inhibitors. Also disclosed are a composition and method for inhibiting hepatitis C (HCV) polymerase, processes for making the compounds, and synthetic intermediates employed in the processes.
